Unveiling Catecholamine Dynamics in Cardiac Health and Disease: Mechanisms, Implications, and Future Perspectives

Wenjing Xiang; Xingyun Wang; Lei Li; Junhui Zeng; Haocheng Lu; Ying Wang

doi:10.53941/ijddp.2023.100012

Abstract

Catecholamines play a pivotal role in regulating both cardiac physiology and pathology, orchestrating the “Fight-or-flight” response through the activation of sympathetic nervous system (SNS) activation and subsequent stimulation of adrenergic receptor. However, chronic stress and various cardiac diseases can disrupt catecholamine balance, contributing to cardiac dysfunction. The synthesis, release, reuptake, and degradation of catecholamines intricately regulate their concentration. Notably, catecholamine dynamics is markedly altered in heart diseases, including heart failure, myocardial infarction, and arrhythmias. While β‍-adrenergic receptor blockers, which block catecholamines from binding to the adrenergic receptors, are widely used in clinical settings, the potential implication of directly manipulating catecholamine homeostasis for the treatment of cardiac diseases have not been extensively explored. This review provides an overview of catecholaminergic systems, and discusses their intricate synthesis, release, uptake, and metabolism within the heart. Additionally, the review highlights mechanisms underlying cardiac effects of catecholamine dysregulation, including contractile dysfunction, electrical remodeling, and cardiac remodeling. Moreover, the review emphasizes the importance of considering spatiotemporal and sexual heterogeneity in catecholamine dynamics for cardiac precision medicine. In terms of future perspectives, we believe that harnessing genetically encoded fluorescent biosensors to map the heterogenous for real-time imaging of catecholamine dynamics and conducting gender-specific dissection of catecholamine dynamics have significant potential to advance personalized management of cardiac diseases management.

References

1.
Bers, D.M. Cardiac excitation-contraction coupling. Nature 2002, 415, 198–205.
2.
Barbagallo, F.; Xu, B.; Reddy, G.R.; et al. Genetically Encoded Biosensors Reveal PKA Hyperphosphorylation on the Myofilaments in Rabbit Heart Failure. Circ. Res. 2016, 119, 931–943.
3.
Liaudet, L.; Calderari, B.; Pacher, P. Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity. Heart Fail. Rev. 2014, 19, 815–824.
4.
Song, Y.; WOO, AY-H.; Zhang, Y.; et al. Cardiac β-Adrenoceptor signaling: The new insight on an old target in the therapy of cardiovascular disease. IJDDP 2022, 1, 3.
5.
Kvetnansky, R.; Sabban, E.L.; Palkovits, M. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol, Rev. 2009, 89, 535–606.
6.
Ebert, S.N.; Rong, Q.; Boe, S.; et al. Catecholamine-synthesizing cells in the embryonic mouse heart. Ann, N, Y, Acad, Sci. 2008, 1148, 317–324.
7.
Tillinger, A.; Novakova, M.; Pavlovicova, M.; et al. Modulation by 6-hydroxydopamine of expression of the phenylethanolamine N-methyltransferase (PNMT) gene in the rat heart during immobilization stress. Stress 2006, 9, 207–213.
8.
Nash, C.A.; Wei, W.; Irannejad, R.; et al. Golgi localized β1-adrenergic receptors stimulate Golgi PI4P hydrolysis by PLCε to regulate cardiac hypertrophy. Elife 2019, 8, e48167.
9.
Wang, Y.; Shi, Q.; Li, M.; et al. Intracellular β1-Adrenergic Receptors and Organic Cation Transporter 3 Mediate Phospholamban Phosphorylation to Enhance Cardiac Contractility. Circ. Res. 2021, 128, 246–261.
10.
Eisenhofer, G.; Kopin, I.J.; Goldstein, D.S. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 2004, 56, 331–349.
11.
Schlessinger, A.; Geier, E.; Fan, H.; et al. Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 15810–15815.
12.
Backs, J.; Haunstetter, A.; Gerber, S.H.; et al. The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation. J. Mol. Cell. Cardiol. 2001, 33, 461–472.
13.
Münch, G.; Rosport, K.; Bültmann, A.; et al. Cardiac overexpression of the norepinephrine transporter uptake-1 results in marked improvement of heart failure. Circ. Res. 2005, 97, 928–936.
14.
Recchia, F.A.; Giacca, M. Targeted uptake-1 carrier to rescue the failing heart. Circ. Res. 2005, 97, 847–849.
15.
Wang, Y.; Zhao, M.; Shi, Q.; et al. Monoamine Oxidases Desensitize Intracellular β1AR Signaling in Heart Failure. Circ. Res. 2021, 129, 965–967.
16.
Hall, K.T.; Battinelli, E.; Chasman, D.I. Catechol-O-Methyltransferase and Cardiovascular Disease: MESA. J. Am. Heart Assoc. 2019, 8, e014986.
17.
Motiejunaite, J.; Amar, L.; Vidal-Petiot, E. Adrenergic receptors and cardiovascular effects of catecholamines. Ann. Endocrinol (Paris). 2021, 82, 193–197.
18.
Gardner, R.T.; Ripplinger, C.M.; Myles, R.C.; et al. Molecular Mechanisms of Sympathetic Remodeling and Arrhythmias. Circ. Arrhythm. Electrophysiol. 2016, 9, e001359.
19.
Francis Stuart, S.D.; Wang, L.; Woodard, W.R.; et al. Age-related changes in cardiac electrophysiology and calcium handling in response to sympathetic nerve stimulation. J. Physiol. 2018, 596, 3977–3991.
20.
Rubart, M.; Zipes, D.P. Mechanisms of sudden cardiac death. J. Clin. Invest. 2005, 115, 2305–2315.
21.
Myles, R.C.; Wang, L.; Kang, C.; et al. Local β-adrenergic stimulation overcomes source-sink mismatch to generate focal arrhythmia. Circ. Res. 2012, 110, 1454–1464.
22.
Myles, R.C.; Wang, L.; Bers, D.M.; et al. Decreased inward rectifying K+ current and increased ryanodine receptor sensitivity synergistically contribute to sustained focal arrhythmia in the intact rabbit heart. J. Physiol. 2015, 593, 1479–1493.
23.
Keller, N.R.; Diedrich, A.; Appalsamy, M.; et al. Norepinephrine transporter-deficient mice exhibit excessive tachycardia and elevated blood pressure with wakefulness and activity. Circulation 2004, 110, 1191–1196.
24.
Xiao, R.P.; Zhang, S.J.; Chakir, K.; et al. Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)--but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. Circulation 2003, 108, 1633–1639.
25.
Wang, Y.; Zhao, M.; Xu, B.; et al. Monoamine oxidase A and organic cation transporter 3 coordinate intracellular β1AR signaling to calibrate cardiac contractile function. Basic Res. Cardiol. 2022, 117, 37.
26.
Xu, B.; Li, M.; Wang, Y.; et al. GRK5 Controls SAP97-Dependent Cardiotoxic β1 Adrenergic Receptor-CaMKII Signaling in Heart Failure. Circ. Res. 2020, 127, 796–810.
27.
Pogwizd, S.M.; Schlotthauer, K.; Li, L.; et al. Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ. Res. 2001, 88, 1159–1167.
28.
Qin, F.; Vulapalli, R.S.; Stevens, S.Y.; et al. Loss of cardiac sympathetic neurotransmitters in heart failure and NE infusion is associated with reduced NGF. Am. J. Physiol. Heart Circ. Physiol. 2002, 282, H363–H371.
29.
Stanton, M.S.; Tuli, M.M.; Radtke, N.L.; et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. J. Am. Coll. Cardiol. 1989, 14, 1519–1526.
30.
Hartikainen, J.; Kuikka, J.; Mäntysaari, M.; et al. Sympathetic reinnervation after acute myocardial infarction. Am. J. Cardiol. 1996, 77, 5–9.
31.
Eschenhagen, T. Is Stimulation of Cardiomyocyte Renewal a Facette of Reversible Catecholamine Toxicity? Circ. Res. 2016, 119, 779–781.
32.
Wallner, M.; Duran, J.M.; Mohsin, S.; et al. Acute Catecholamine Exposure Causes Reversible Myocyte Injury Without Cardiac Regeneration. Circ. Res. 2016, 119, 865–879.
33.
Rona, G. Catecholamine cardiotoxicity. J. Mol. Cell. Cardiol. 1985, 17, 291–306.
34.
Du, Y.; Demillard, L.J.; Ren, J. Catecholamine-induced cardiotoxicity: A critical element in the pathophysiology of stroke-induced heart injury. Life Sci. 2021, 287, 120106.
35.
Xiao, H.; Li, H.; Wang, J.J.; et al. IL-18 cleavage triggers cardiac inflammation and fibrosis upon β-adrenergic insult. Eur. Heart, J. 2018, 39, 60–69.
36.
Meier, H.; Bullinger, J.; Marx, G.; et al. Crucial role of interleukin-6 in the development of norepinephrine-induced left ventricular remodeling in mice. Cell. Physiol. Biochem. 2009, 23, 327–334.
37.
Wang, Y.; Hu, H.; Yin, J.; et al. TLR4 participates in sympathetic hyperactivity Post-MI in the PVN by regulating NF-κB pathway and ROS production. Redox. Biol. 2019, 24, 101186.
38.
Costa, V.M.; Carvalho, F.; Bastos, M.L.; et al. Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases. Curr. Med. Chem. 2011, 18, 2272–2314.
39.
Kaludercic, N.; Mialet-Perez, J.; Paolocci, N.; et al. Parini A, Di Lisa, F. Monoamine oxidases as sources of oxidants in the heart. J. Mol. Cell. Cardiol. 2014, 73, 34–42.
40.
Di Sante, M.; Antonucci, S.; Pontarollo, L.; et al. Monoamine oxidase A-dependent ROS formation modulates human cardiomyocyte differentiation through AKT and WNT activation. Basic Res. Cardiol. 2023, 118, 4.
41.
Kaludercic, N.; Carpi, A.; Menabò R.; et al. Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim. Biophys. Acta. 2011, 1813, 1323–1332.
42.
Wright, C.D.; Chen, Q.; Baye, N.L.; et al. Nuclear alpha1-adrenergic receptors signal activated ERK localization to caveolae in adult cardiac myocytes. Circ. Res. 2008, 103, 992–1000.
43.
Subramaniam, G.; Schleicher, K.; Kovanich, D.; et al. Integrated Proteomics Unveils Nuclear PDE3A2 as a Regulator of Cardiac Myocyte Hypertrophy. Circ. Res. 2023, 132, 828–848.
44.
Wolff, D.W.; Dang, H.K.; Liu, M.F.; et al. Distribution of alpha1-adrenergic receptor mRNA species in rat heart. J. Cardiovasc. Pharmacol. 1998, 32, 117–122.
45.
Brodde, O.E.; Bruck, H.; Leineweber, K.; et al. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res. Cardiol. 2001, 96, 528–538.
46.
Ostadal, B.; Ostadal, P. Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications. Br. J. Pharmacol. 2014, 171, 541–554.
47.
Ji, H.; Kwan, A.C.; Chen, M.T.; et al. Sex Differences in Myocardial and Vascular Aging. Circ. Res. 2022, 130, 566–577.
48.
Brogden, R.N.; Heel, R.C.; Speight, T.M.; et al. alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use. Drugs, 1981, 21, 81–89.
49.
Mandela, P.; Chandley, M.; Xu, Y.Y.; et al. Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles. Neurochem. Int. 2010, 56, 760–767.
50.
Bourin, M.; Chue, P.; Guillon, Y. Paroxetine: a review. CNS Drug Rev. 2001, 7, 25–47.
51.
Guo, J.; Tang, R. Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A systematic review and meta-analysis. Medicine (Baltimore) 2021, 100, e26955.
52.
Wang, Q.; Wang, Y.; West, T.M.; et al. Carvedilol induces biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility. Cardiovasc. Res. 2021, 117, 2237–2251.
53.
Guillem, K.; Vouillac, C.; Azar, M.R.; et al. Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J. Neurosci. 2005, 25, 8593–8600.
54.
Graf, W.D.; Unis, A.S.; Yates, C.M.; et al. Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism. Neurology 2001, 57, 410–416.
55.
Jing, M.; Zhang, Y.; Wang, H.; et al. G-protein-coupled receptor-based sensors for imaging neurochemicals with high sensitivity and specificity. J. Neurochem. 2019, 151, 279–288.
56.
Wang, H.; Jing, M.; Li, Y. Lighting up the brain: genetically encoded fluorescent sensors for imaging neurotransmitters and neuromodulators. Curr. Opin. Neurobiol. 2018, 50, 171–178.
57.
Nakanishi, J.; Takarada, T.; Yunoki, S.; et al. FRET-based monitoring of conformational change of the beta2 adrenergic receptor in living cells. Biochem. Biophys. Res. Commun. 2006, 343, 1191–1196.
58.
Feng, J.; Zhang, C.; Lischinsky, J.E.; et al. A Genetically Encoded Fluorescent Sensor for Rapid and Specific In Vivo Detection of Norepinephrine. Neuron 2019, 102, 745–761.
59.
Muller, A.; Joseph, V.; Slesinger, P.A.; et al. Cell-based reporters reveal in vivo dynamics of dopamine and norepinephrine release in murine cortex. Nat. Methods 2014, 11, 1245–1252.
60.
Surdo, N.C.; Berrera, M.; Koschinski, A.; et al. FRET biosensor uncovers cAMP nano-domains at β-adrenergic targets that dictate precise tuning of cardiac contractility. Nat. Commun. 2017, 8, 15031.
61.
Inagaki, H.K.; Ben-Tabou de-Leon, S.; Wong, A.M.; et al. Visualizing neuromodulation in vivo: TANGO-mapping of dopamine signaling reveals appetite control of sugar sensing. Cell 2012, 148, 583–595.
62.
Caldwell, J.L.; Lee, I.J.; Ngo, L.; et al. Whole-heart multiparametric optical imaging reveals sex-dependent heterogeneity in cAMP signaling and repolarization kinetics. Sci. Adv. 2023, 9, eadd5799.
63.
Fazal, L.; Azibani, F.; Vodovar, N.; et al. Effects of biological sex on the pathophysiology of the heart. Br. J. Pharmacol. 2014, 71, 555–566.
64.
Luczak, E.D.; Leinwand, L.A. Sex-based cardiac physiology. Annu. Rev. Physiol. 2009, 71, 1–18.
65.
Yue, Q.; Wang, K.; Guan, M.; et al. Single-Vesicle Electrochemistry Reveals Sex Difference in Vesicular Storage and Release of Catecholamine. Angew. Chem. Int. Ed. Engl. 2022, 61, e202117596.
66.
Mitoff, P.R.; Gam, D.; Ivanov, J.; et al. Cardiac-specific sympathetic activation in men and women with and without heart failure. Heart 2011, 97, 382–387.
67.
Cingolani, O.H.; Kaludercic, N.; Paolocci, N. Sexual dimorphism in cardiac norepinephrine spillover: A NET difference. Heart 2011, 97, 347–349.
68.
Grimsby, J.; Toth, M.; Chen, K.; et al. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat. Genet. 1997, 17, 206–210.
69.
Jiang, H.; Xie, T.; Ramsden, D.B.; Ho, S.L. Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology 2003, 45, 1011–1018.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us